Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

  Pacini, F ^a   Castagna, M G ^a   Brilli, L ^a   Pentheroudakis, G ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BLEOMYCIN; CABOZANTINIB; CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IODINE 131; LEVOTHYROXINE; MOTESANIB; PACLITAXEL; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB;

ABLATION THERAPY; ANAPLASTIC THYROID CANCER; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL EFFECTIVENESS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MUCOSA INFLAMMATION; NAUSEA; NEEDLE BIOPSY; OUTCOME ASSESSMENT; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT INDICATION; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE;

EID: 84866629839     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds230     Document Type: Article

References (40)

1. Aschebrook-Kilfoy B, Ward MH, Sabra MM et al. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 2011; 21: 125-134.
2. Howlader N, Noone AM, Krapcho M (eds) et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute 2011 http://seer.cancer. gov/csr/1975_2008/ based on November 2010 SEER data submission, posted to the SEER web site.
3. Leenhardt L, Bernier MO, Boin-Pineau MH et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 2004; 150: 133-139.
4. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cance in the United States, 1988-2005. Cancer 2009; 115: 3801-3807.
5. Tronko MD, Bogdanova TI, Komissarenko IV et al. Thyroid carcinoma in children and adolescents in Ukraine after the Chernobyl nuclear accident: statistical data and clinicomorphologic characteristics. Cancer 1999; 86: 149-156.
6. Dean DS, Gharib H. Epidemiology of Thyroid Nodules. Best Pract Res Clin Endocrinol Metab 2008; 22: 901-911.
7. Pacini F, Schlumberger M, Dralle H et al. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
8. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
9. Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the ?ne-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94: 2092-2098.
10. Cantara S, Capezzone M, Marchisotta S et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95: 1365-1369.
11. 2009 AJCC Cancer Staging Manual, 7th edition. New York: Springer-Verlag.
12. Tuttle RM, Tala H, Shah J et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the DRS American Thyroid Association staging system. Thyroid 2010; 20: 1341-1349.
13. Castagna MG, Maino F, Cipri C et al. Delayed risk strati?cation, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011; 165: 441-446.
14. Pacini F, Ladenson PW, Schlumberger M et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol 2006; 91: 926-932.
15. Pilli T, Brianzoni E, Capoccetti F et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin- stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92: 3542-3546.
16. Chianelli M, Todino V, Graziano FM et al. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 2009; 160: 431-436.
17. Elisei R, Schlumberger M, Driedger A et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 2009; 94: 4171-4179.
18. Tuttle RM, Brokhin M, Omry G et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008; 49: 764-770.
19. Tuttle RM, Lopez N, Leboeuf R et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 2010; 20: 257-263.
20. Brassard M, Borget I, Edet-Sanson A et al. THYRDIAG Working Group. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011; 96: 1352-1359.
21. Castagna MG, Tala Jury HP, Cipri C et al. The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest 2011; 34: 219-223.
22. Malandrino P, Latina A, Marescalco S et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 2011; 96: 1703-1709.
23. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005; 90: 5047-5057.
24. Castagna MG, Brilli L, Pilli T et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008; 93: 76-81.
25. Crocetti U, Durante C, Attard M et al. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. Thyroid 2008; 18: 1049-1053.
26. Kloos RT. Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. J Clin Endocrinol Metab 2010; 95: 5241-5248.
27. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]?uoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91: 498-505.
28. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-2899.
29. Kapiteijn E, Schneider TC, Morreau H et al. New treatment modalities in advanced thyroid cancer. Ann Oncol 2012; 23: 10-18.
30. Brilli L, Pacini F. Targeted therapy in refractory thyroid cancer: current achievements and limitations. Future Oncol 2011; 7: 657-668.
31. Hovens GC, Stokkel MP, Kievit J et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92: 2610-2615.
32. American Thyroid Association Guidelines Task Force. Kloos RT, Eng C, Evans DB et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565-612.
33. Machens A, Schneyer U, Holzhausen HJ et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005; 90: 2029-2034.
34. Laure Giraudet A, Al Ghulzan A, Aupérin A et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008; 158: 239-246.
35. Wells SA, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134-141.
36. DeLellis RA, Lloyd R, Heitz PU (eds). WHO Classification of Tumors, Pathology and Genetics Tumors of Endocrine Organs. Lyonn, France: IARC Press 2004; 73-76.
37. Volante M, Landolfi S, Chiusa L et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 2004; 100: 950-957.
38. Wreesmann VB, Ghossein RA, Patel SG et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol 2002; 161: 1549-1556.
39. Neff RL, Farrar WB, Kloos RT et al. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008; 37: 525-538.
40. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16: 17-44.